Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
KRYSTAL BIOTECH RG (NQ: KRYS)
9.100 USD  +0.110 (+1.22%)
Official Closing Price  /  Updated: 8:00 PM EDT, Apr 24, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 15,934
Open 9.260
Bid (Size) 9.000 (1000)
Ask (Size) 11.70 (300)
Prev. Close 8.990
Today's Range 8.910 - 9.301
52wk Range 8.030 - 12.00
Shares Outstanding 10,309,615
Dividend Yield N/A
Performance
YTD
-0.87%
-0.87%
1 Month
-8.27%
-8.27%
3 Month
-6.67%
-6.67%
6 Month
-5.89%
-5.89%
1 Year
-14.47%
-14.47%
Top News
More News
Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. (“Krystal”) (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announces... Read More
from GlobeNewswire News Releases
Krystal Biotech Presents Their Skin TARgeted Delivery Platform at the World Orphan Drug Congress USA
Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases, today announces a presentation on the Company’s... Read More
from GlobeNewswire News Releases
More News
Read More
Krystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis Bullosa
from GlobeNewswire News Releases
Krystal Biotech Reports 2017 Financial Results and Business Progress
from GlobeNewswire News Releases
Krystal Biotech, Inc. to Present at the 30th Annual ROTH Conference
from GlobeNewswire News Releases
Krystal Biotech, Inc. Announces Granting of U.S. Composition of Matter Patent Covering Herpes Simplex Virus (HSV) Vectors and Methods of Using the Same to Treat Skin Diseases
from GlobeNewswire News Releases
Krystal Biotech Reports that KB103 Received Clearance From RAC Review and Announces Third Quarter 2017 Financial Results
from GlobeNewswire News Releases
Krystal Biotech’s KB103 Granted Orphan Drug Designation by the FDA to Treat Patients With Dystrophic Epidermolysis Bullosa
from GlobeNewswire News Releases
Krystal Biotech Receives Equity-Based Award from EB Research Partnership and EB Medical Research Foundation
from GlobeNewswire News Releases
Krystal Biotech Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
from GlobeNewswire News Releases
Krystal Biotech Announces Presentation of KB103 Data at EB2017 - The 5th World Conference of EB Research
from GlobeNewswire News Releases
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial